long-term production.-1-Table of ContentsProduct CandidatesThe following table summarizes certain information about our product candidates:ProductCandidateBrandedReference DrugCollaboration PartnerIndicationExpected Status/MilestonesBiosimilars(1)PF582 -RanibizumabLucentisHospiraWet age-related macular degeneration(2)Phase 1b/2a in-process – Phase 3 commencing in 2016PF530 – Interferon beta-1bBetaseronWholly-OwnedRelapsing multiple sclerosis(3)Phase 1 initiated in March 2015GenericsPF708 – TeriparatideForteoWholly-OwnedOsteoporosisANDA enabling PK study commencing in the second half of 2015Novel VaccinesPx563L – rPAbased Anthrax VaccineN/AU.S. Government FundedAnthrax vaccinePhase 1a commencing in the second half of 2015Px533 Malaria VaccineN/AU.S. Government FundedMalaria vaccinePhase 1 commencing in 2015(1)To the extent our biosimilar products are approved for use in the United States and European Union at a future date, we believe that our biosimilar products will be
to, the following:•We have a limited operating history and expect to generate significant losses for the foreseeable future;•Even if this offering is successful, we will require substantial additional funds to obtain regulatory approval for and commercialize our two most
to maintain our current strategic relationships with Hospira and Strides Arcolab, our business, commercialization prospects and financial condition may be materially adversely affected;•The approval processes of the FDA, EMA, and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we and our
failure to become and remain profitable could depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.Even if the offering is successful, we expect that we will require substantial additional funds to obtain regulatory approval for and commercialize
Our future capital requirements may vary depending on the following:•the continued progress in our research and development programs, including completion of our preclinical studies and clinical trials;•the time and costs involved in obtaining regulatory and marketing approvals in multiple jurisdictions for our product candidates that successfully
including:•variations in the level of expenses related to our PF582 and PF530 development programs;•addition or termination of clinical trials;•any intellectual property infringement lawsuit in which we may become involved;•regulatory developments affecting any of our products; and-13-Table of Contents•our execution of any service, collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these
any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.In addition, if we and our collaboration partners are successful in commercializing PF582 and PF530 or any other product candidates the
In order to effectively execute our growth strategy, we will be required to:•manage our clinical trials effectively;•identify, recruit, retain, incentivize and integrate additional employees;•establish and maintain collaborations with third parties for the development and commercialization of our product candidates, or otherwise build and
maintain a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;•manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and•continue to improve our operational, financial and management controls, reporting systems and procedures.Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able
Factors that could materially adversely affect our U.S. government contracting business include:•budgetary constraints affecting U.S. government spending generally, or specific departments or agencies in particular;•changes in U.S. government fiscal policies or available funding;•changes in U.S. government defense and homeland security priorities;•changes in U.S. government programs or requirements;•U.S. government curtailment of its use of technology services firms;•adoption of new laws or regulations;•technological developments;•U.S. government shutdowns, threatened shutdowns or budget delays;-18-Table of Contents•competition and consolidation in our industry; and•general economic conditions.These or other factors could cause U.S. government departments or agencies to reduce their development funding or future purchases under contracts, to exercise their right to terminate contracts or fail
by imposing equitable price adjustments;•audit contract-related costs and fees, including allocated indirect costs;•claim rights, including intellectual property rights, in products and data developed under such agreements;•suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;•impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such contracts;•suspend or debar the contractor from doing future business with the government;•decline to exercise an option to renew a contract;•exercise an option to purchase only the minimum amount, if any, specified in a contract;•decline to exercise an option to purchase the maximum amount, if any, specified in a contract;•claim rights to facilities or to products, including intellectual property, developed under the contract;•require repayment of contract funds spent on construction of facilities in the event of contract default;•take actions that result in a longer development timeline than expected;•change the course of a development program in a manner that differs from the contract’s original terms or from our desired development plan,
merits or eventual outcome, liability claims may result in:•decreased demand for PF582, PF530 or any future product candidates or products we develop;•injury to our reputation and significant negative media attention;•withdrawal of clinical trial participants or cancellation of clinical trials;•costs to defend the related litigation;•a diversion of management’s time and our resources;•substantial monetary awards to trial participants or patients;•regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;•loss of revenue; and•the inability to commercialize any products we develop.Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could impact the
the collaboration, or commercialize such product candidates, or the termination of our agreement with Hospira or Strides Arcolab, as applicable, may have a material adverse effect on our business, results of operations and financial condition.Our existing product development and/or commercialization arrangements, and any that we may enter into in the future, may not be
product resulting in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources;•the results of our clinical trials may not match our collaboration partners’ expectations, even if statistically significant;•a collaboration partner may not adequately protect or enforce the intellectual property rights associated with a product or product candidate; and•a collaboration partner may use our proprietary information or intellectual property in such a way as to invite litigation from a third party.Any such activities by our current or future collaboration partners could adversely affect us financially
which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the accurate and satisfactory performance of third party contractors, including our collaborators;•timely receipt of necessary marketing approvals from the FDA, the EU Commission, and similar foreign regulatory authorities;•maintaining an acceptable safety and adverse event profile of our products following approval;•achieving and maintaining compliance with all regulatory requirements applicable to our product candidates or any approved products;•making arrangements with third party manufacturers for, or establishing, commercial manufacturing capabilities;-35-Table of Contents•launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;•obtaining and maintaining patent and trade secret protection and regulatory exclusivity, where available, for our product candidates;•the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;•acceptance of our products, if and when approved, by patients, the medical community and third party payors; and•the ability to raise additional capital on acceptable terms to achieve our goals.If we and our collaboration partners are unable to obtain regulatory approval for one or both of these product candidates in a timely